98 related articles for article (PubMed ID: 11110053)
1. Apolipoprotein E polymorphism and breast carcinoma: correlation with cell proliferation indices and clinical outcome.
Zunarelli E; Nicoll JA; Migaldi M; Trentini GP
Breast Cancer Res Treat; 2000 Oct; 63(3):193-8. PubMed ID: 11110053
[TBL] [Abstract][Full Text] [Related]
2. Apolipoprotein E polymorphism and central nervous system tumors: correlation with cell proliferation indices and clinical outcome.
Zunarelli E; Nicoll JA; Trentini GP
Clin Neuropathol; 2000; 19(1):1-6. PubMed ID: 10774944
[TBL] [Abstract][Full Text] [Related]
3. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables.
Depowski PL; Rosenthal SI; Brien TP; Stylos S; Johnson RL; Ross JS
Mod Pathol; 2000 May; 13(5):542-7. PubMed ID: 10824926
[TBL] [Abstract][Full Text] [Related]
4. Influences of apolipoprotein E polymorphism on the risk for breast cancer and HER2/neu status in Taiwan.
Chang NW; Chen DR; Wu CT; Aouizerat BE; Chen FN; Hung SJ; Wang SH; Wei MF; Chang CS
Breast Cancer Res Treat; 2005 Apr; 90(3):257-61. PubMed ID: 15830139
[TBL] [Abstract][Full Text] [Related]
5. Pleomorphic lobular carcinoma of the breast: its cell kinetics, expression of oncogenes and tumour suppressor genes compared with invasive ductal carcinomas and classical infiltrating lobular carcinomas.
Frolik D; Caduff R; Varga Z
Histopathology; 2001 Nov; 39(5):503-13. PubMed ID: 11737309
[TBL] [Abstract][Full Text] [Related]
6. MIB-1 proliferative activity in invasive breast cancer measured by image analysis.
Querzoli P; Albonico G; Ferretti S; Rinaldi R; Magri E; Indelli M; Nenci I
J Clin Pathol; 1996 Nov; 49(11):926-30. PubMed ID: 8944614
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical assessment of proliferation rate of breast carcinoma cells using Ki-67, MIB-1 and anti-PCNA monoclonal antibodies.
Markiewski M; Domagała W
Pol J Pathol; 1996; 47(4):189-94. PubMed ID: 9097711
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor expression in male breast carcinoma: lack of clinicopathological association.
Pich A; Margaria E; Chiusa L; Candelaresi G; Dal Canton O
Br J Cancer; 1999 Feb; 79(5-6):959-64. PubMed ID: 10070897
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of ER, PR, MIB-1, pS2, and nuclear grade in FNA specimens of cT1 breast carcinomas: clinicopathological correlation.
Angelidou E; Politi E; Sotiropoulou G; Poulianou E; Koutselini H
Diagn Cytopathol; 2006 Aug; 34(8):547-52. PubMed ID: 16850494
[TBL] [Abstract][Full Text] [Related]
10. Correlation of growth fraction by Ki-67 and proliferating cell nuclear antigen (PCNA) immunohistochemistry with histopathological parameters and prognosis in primary breast carcinomas.
Haerslev T; Jacobsen GK; Zedeler K
Breast Cancer Res Treat; 1996; 37(2):101-13. PubMed ID: 8750578
[TBL] [Abstract][Full Text] [Related]
11. [Effect of the proliferation rate on the course of node negative breast carcinoma].
Mitze M; Weikel W; Brumm C; Lippold R; Knapstein PG
Geburtshilfe Frauenheilkd; 1995 Jun; 55(6):299-305. PubMed ID: 7657137
[TBL] [Abstract][Full Text] [Related]
12. Relationship of DNA ploidy to hormone receptor status and proliferation in invasive breast carcinoma.
Spiethoff A; Schenck A; Bohrer M
J Cancer Res Clin Oncol; 2000 Dec; 126(12):707-10. PubMed ID: 11153143
[TBL] [Abstract][Full Text] [Related]
13. Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value.
Spyratos F; Ferrero-Poüs M; Trassard M; Hacène K; Phillips E; Tubiana-Hulin M; Le Doussal V
Cancer; 2002 Apr; 94(8):2151-9. PubMed ID: 12001111
[TBL] [Abstract][Full Text] [Related]
14. MIB1 proliferation index in breast infiltrating carcinoma: comparison with other proliferative markers and association with new biological prognostic factors.
González-Vela MC; Garijo MF; Fernández F; Val-Bernal JF
Histol Histopathol; 2001 Apr; 16(2):399-406. PubMed ID: 11332695
[TBL] [Abstract][Full Text] [Related]
15. A simple index using video image analysis to predict disease outcome in primary breast cancer.
Lockwood CA; Ricciardelli C; Raymond WA; Seshadri R; McCaul K; Horsfall DJ
Int J Cancer; 1999 Jun; 84(3):203-8. PubMed ID: 10371334
[TBL] [Abstract][Full Text] [Related]
16. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
Yan J; Liu XL; Han LZ; Xiao G; Li NL; Deng YN; Yin LC; Ling LJ; Yu XY; Tan CL; Huang XP; Liu LX
Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532
[TBL] [Abstract][Full Text] [Related]
17. A comparison of cell cycle markers in well-differentiated lobular and ductal carcinomas.
Soslow RA; Carlson DL; Horenstein MG; Osborne MP
Breast Cancer Res Treat; 2000 May; 61(2):161-70. PubMed ID: 10942102
[TBL] [Abstract][Full Text] [Related]
18. Comparison of quantitative and semiquantitative methods of assessing MIB-1 with the S-phase fraction in breast carcinoma.
MacGrogan G; Jollet I; Huet S; Sierankowski G; Picot V; Bonichon F; Coindre JM
Mod Pathol; 1997 Aug; 10(8):769-76. PubMed ID: 9267818
[TBL] [Abstract][Full Text] [Related]
19. Association between the apolipoprotein E genotypes and breast cancer patients in Taiwanese.
Chang SJ; Hou MF; Tsai SM; Kao JT; Wu SH; Hou LA; Tsai LY
Breast Cancer Res Treat; 2006 Jul; 98(1):109-13. PubMed ID: 16752225
[TBL] [Abstract][Full Text] [Related]
20. Correlation of astrocyte elevated gene-1, basic-fibroblast growth factor, beta-catenin, Ki-67, tumor necrosis factor-alfa with prognostic parameters in ductal carcinomas and ductal intraepithelial neoplasms.
Erdem H; Gundogdu B; Ankarali H; Yasar M; Sener E; Oktay M; Bahadir A; Uzunlar AK; Gursan N; Ozaydin I; Sahiner C
Niger J Clin Pract; 2015; 18(5):638-43. PubMed ID: 26096243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
